Daré Bioscience Sees Opportunity in New US Women’s Health Initiative
Daré Bioscience said it sees opportunities from a new US initiative focused on women’s health.
Related stories
Nasdaq halts trading for volatility at 09:30 a.m.
M impact | EQUITY | Oct 29, 2026, 01:39 PM UTC
S&P 500 Falls 37.96 Points (0.49%)
M impact | EQUITY | Oct 29, 2026, 01:33 PM UTC
DJIA Falls 187.84 Points (0.36%)
M impact | EQUITY | Oct 29, 2026, 01:33 PM UTC
Analysts Cut Boston Scientific Ratings and Price Targets After Q3
Jefferies downgraded Boston Scientific to Hold from Buy with a $46 price target, and JPMorgan moved to Neutral from Overweight with a $46 target. Oppenheimer cut its rating to Mark
M impact | EQUITY | Oct 29, 2026, 01:33 PM UTC
Analysts Raise Gen Digital Price Targets After Fiscal Q2 Results
Morgan Stanley raised its target to $34 from $32, Jefferies to $29 from $27, and RBC to $27 from $24 while maintaining a Sector Perform rating. The changes follow Gen Digital’s fis
M impact | EQUITY | Oct 29, 2026, 01:33 PM UTC
Nasdaq halts trading for volatility at 9:32 a.m.
M impact | EQUITY | Oct 29, 2026, 01:32 PM UTC